Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS - PubMed
3 hours ago
- #biomarkers
- #neuroinflammation
- #multiple sclerosis
- Dimethyl fumarate (DMF) reduced serum GFAP levels, indicating potential impact on chronic disease processes in MS, while rituximab (RTX) did not.
- Both DMF and RTX significantly lowered serum neurofilament light chain (sNfL) levels, reflecting suppression of acute inflammatory activity in relapsing-remitting MS.
- DMF was associated with a lower risk of progression independent of relapse and MRI activity (PIRMA), suggesting benefits beyond peripheral immune modulation.